Paradigm Biocapital Advisors LP Xenon Pharmaceuticals Inc. Transaction History

Paradigm Biocapital Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $16 Million - $19.3 Million	-441,594 Reduced 17.77%	2,043,280 $79.7 Million
Q1 2024 May 15, 2024	BUY	$42.66 - $50.04 $15.2 Million - $17.9 Million	357,474 Added 16.8%	2,484,874 $107 Million
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $18.2 Million - $29.5 Million	635,565 Added 42.6%	2,127,400 $98 Million
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $17.2 Million - $20 Million	502,508 Added 50.79%	1,491,835 $51 Million
Q2 2023 Aug 14, 2023	BUY	$34.84 - $43.54 $11.8 Million - $14.7 Million	338,259 Added 51.95%	989,327 $38.1 Million
Q1 2023 May 15, 2023	BUY	$33.46 - $40.35 $21.8 Million - $26.3 Million	651,068 New	651,068 $23.3 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.